logo

Stealth Biotherapeutics Corp (MITO)



Trade MITO now with
  Date
  Headline
6/27/2022 7:32:30 AM Stealth BioTherapeutics Says Received Preliminary Non-Binding Proposal
6/14/2022 7:27:19 AM Stealth Granted Pre-NDA Meeting For Elamipretide As Potential Treatment For Barth Syndrome
6/8/2022 7:23:23 AM Stealth BioTherapeutics Presents New SBT-272 Preclinical Data
5/31/2022 7:59:36 AM Stealth BioTherapeutics Gets ODD From EMA For Elamipretide For Myopathic Mitochondrial DNA Depletion Syndrome
5/23/2022 7:33:50 AM Stealth BioTherapeutics Announces Data From Phase 2 ReCLAIM-2 Study Of Elamipretide In Geographic Atrophy
5/12/2022 7:37:47 AM Stealth Receives FDA Orphan Drug Designation For Elamipretide For Treatment Of Duchenne Muscular Dystrophy
5/2/2022 7:34:54 AM Stealth Bio : Phase 2 Trial Of Elamipretide In Low Luminance Visual Acuity Did Not Meet Primary Endpoints
4/11/2022 8:31:45 AM Stealth BioTherapeutics Announces $8.5 Mln In Equity Financings
3/28/2022 7:38:55 AM Stealth BioTherapeutics Gets Orphan Drug Designation From FDA For Elamipretide For Friedreich's Ataxia; Stock Up
2/15/2022 7:33:35 AM Stealth BioTherapeutics Says Last Patient Completes Treatment In Phase 2 Geographic Atrophy Clinical Trial
2/8/2022 7:40:11 AM Stealth Announces Oral Presentation Of New Duchenne Muscular Dystrophy Data
12/20/2021 7:34:53 AM Stealth BioTherapeutics Reports Positive Pre-IND Meeting For Duchenne Muscular Dystrophy